Optimization of the prostaglandin F2α receptor for structural biology
PLOS One · 2025
DOI: 10.1371/journal.pone.0320114 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Marine Salze und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada. Hauptthemen laut MEDLINE: Receptors, Prostaglandin, Protein Engineering. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada.
Abstract (Originalsprache)
Prostaglandin F 2ɑ (PGF 2ɑ ) is a bioactive lipid derived from arachidonic acid and is involved in many physiological and pathophysiological processes, such as parturition, vascular tone regulation, glaucoma and inflammation. It acts by binding to the Prostaglandin F 2ɑ receptor (FP), a G Protein-Coupled Receptor (GPCR) that mediates signaling events by engaging intracellular heterotrimeric G protein effectors. The orthosteric binding site of lipid-binding receptors displays greater efficacy-dependent plasticity that hinders the design of ligands. Solving the structure of FP with ligands of different efficacies at an atomic level is important to fully understand its mechanism of activation and inhibition. Most purified FP-ligand complexes are unstable in vitro . The development of new X-ray crystallography and single particle cryo-electron microscopy (cryoEM) strategies to understand receptors’ signal transduction requires improved purification yield and in vitro stability of the receptor. Here, we present a protein engineering effort to optimize the FP protein sequence for use in structural biology. Strategies involve protein insertion sites in the third intracellular loop (ICL3), N-terminal and C-terminal deletions, and single-point mutations that favorably affect receptor purification yield and stability in vitro . The best FP construct displays a yield of 1.5 mg/L and a stability of 59 o C, which constitute a threefold improvement in purification yield and 9 o C increase in stability over the wild-type receptor. These modifications in the receptor are suitable for pursuing alternative strategies for improving FP purification yield and for studying FP binding efficacy to its ligands through structural biology approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.
- Division of Clinical and Translational Research, Department of Medicine, McGill University, Montréal, Québec, Canada.
- Department of Medicine, McGill University Health Center, McGill University, Montréal, Québec, Canada.
- Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec, Canada.
- Centre de Recherche du CHUS, CIUSSS-Estrie-CHUS, Sherbrooke, Québec, Canada.
ORCID-Profile: Marine Salze, Tegvir S Boora, Martin Audet
Förderung
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada
Zitieren
APA
Salze, M., Chrétien, S., Boora, T. S., Macovei, M., Barbeau, E., Blais, V., Laporte, S. A., & Audet, M. (2025). Optimization of the prostaglandin F2α receptor for structural biology. PLOS One. https://doi.org/10.1371/journal.pone.0320114
Vancouver
Salze M, Chrétien S, Boora TS, Macovei M, Barbeau E, Blais V, et al. Optimization of the prostaglandin F2α receptor for structural biology. PLOS One. 2025. doi:10.1371/journal.pone.0320114
BibTeX
@article{Salze2025,
author = {Salze, Marine and Chrétien, Sébastien and Boora, Tegvir S and Macovei, Madalina and Barbeau, Eric and Blais, Véronique and Laporte, Stéphane A and Audet, Martin},
title = {Optimization of the prostaglandin F2α receptor for structural biology},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0320114}
}
EUVIMED